Core Insights - Iovance Biotherapeutics announced five-year results from the Phase 2 C-144-01 clinical trial for Amtagvi, demonstrating a five-year overall survival rate of 20% in patients with advanced melanoma previously treated with immune checkpoint inhibitors [1][2][3] Clinical Trial Results - The C-144-01 trial involved 153 patients with advanced melanoma, showing a median overall survival (OS) of 13.9 months and an objective response rate of 31.4%, with complete responses in 5.9% and partial responses in 25.5% of patients [3][7] - Among responders, the median duration of response was 36.5 months, with 31.3% of responders maintaining ongoing responses at the five-year assessment [3][5] Safety Profile - Adverse events were consistent with known safety profiles of nonmyeloablative lymphodepletion and interleukin-2 administration, with a rapid decrease in incidence within the first two weeks post-infusion and no new or late-onset treatment-related adverse events reported [4][5] Regulatory Approval - The U.S. FDA granted accelerated approval to Amtagvi in February 2024 for adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, marking it as the first one-time T cell therapy for solid tumors [7][11] Future Developments - Iovance is conducting the TILVANCE-301 Phase 3 trial to confirm the clinical benefit of Amtagvi in frontline advanced melanoma [7][10]

Core Insights - Iovance Biotherapeutics is under investigation for potential violations of federal securities laws and unlawful business practices [1] - The company reported a significant decline in first quarter 2025 product revenue, totaling $49.3 million, down from $73.7 million in the previous quarter [3] - Iovance has revised its full fiscal year 2025 revenue guidance from a range of $450 million-$475 million to $250 million-$300 million, representing a reduction of over 40% at the midpoint [3] - Following the announcement, Iovance's share price dropped by $1.42, or approximately 44%, closing at $1.75 on May 9, 2025 [3] Company Performance - The first quarter 2025 product revenue of $49.3 million indicates a significant decrease compared to the previous quarter's revenue of $73.7 million [3] - The revision of the full-year 2025 revenue guidance reflects challenges in the launch dynamics of the T cell immunotherapy, Amtagvi (lifileucel), which was launched in the U.S. in the first half of 2024 [3] Market Reaction - The announcement of the revenue decline and guidance revision led to a sharp decline in Iovance's stock price, falling from $3.17 to $1.75 within a day [3]